I became interested in medical research after seeing the human suffering that results from contracting dangerous infectious diseases, especially in resource-poor countries. My research work is focused on preventing these infections through the use of current and novel vaccines. I believe with my knowledge and skills, I can contribute to reducing the incidence of, or even eliminating, certain infectious diseases. My goal is to mitigate the suffering caused by infectious diseases.
My research interests include the study of immunology, infectious diseases, autoimmune diseases, vaccine development and translation of knowledge gained from the bench to the clinic. I have been in research for over 28 years, and I began my work at Cincinnati Children’s in 2016.
In my lab, we are working to develop and evaluate novel candidate Ebola vaccines on virus-like-particles (VLPs) platform. Surface glycoproteins (GPs) from different Ebola species are expressed on different VLP matrices. Their potential to induce cross-protective immunity against different Ebola viruses will be studied in non-human primate models of Ebola virus disease (EVD). We are also focused on studying innate immune responses triggered by Ebola virus infections and how Ebola viruses evade innate barriers. In addition, we are researching the role of regulatory T cells (Tregs) in both health and disease.
One of our most notable recent discoveries includes the development and immunogenicity evaluation of a new universal Ebola vaccine that may fight all four virus species that infect humans. See more information.
Some of our additional discoveries include:
It is my honor to have received several awards, including:
MS: Panjab University, Chandigarh, India, 1991.
PhD: Post Graduate Institute of Medical Education and Research, Chandigarh, India, 1998.
Postdoc: Rutgers University, Emory University.
Immunology; infectious diseases; vaccine development and translation; autoimmune diseases.
Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells. JCI insight. 2022; 7.
Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. Frontiers in Immunology. 2021; 12.
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. Journal of Virology. 2020; 94.
IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer. Blood Advances. 2020; 4:1594-1605.
A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay. Journal of Immunological Methods. 2018; 460:10-16.
Karnail Singh, PhD, Paul Spearman, MD4/16/2020